BridgeBio Oncology Therapeutics (BBOT) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T21:31:01.665Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:31:01.665Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 3.5
Unrounded diluted TTM EPS · period ending 2026-06-30: N/A

FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

BBOT PE Ratio Metrics

PE RATIO

N/A

BBOT Competitors' PE Ratio

BBOT

BridgeBio Oncology Therapeutics Inc.

Current

Market Cap

$280.37M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FULC

Fulcrum Therapeutics, Inc.

vs BBOT

Market Cap

$281.54M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LAB

Standard BioTools Inc.

vs BBOT

Market Cap

$282.64M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACB

Aurora Cannabis Inc.

vs BBOT

Market Cap

$284.31M

PE Ratio

N/A

TTM Avg

46.08

3Y Avg

46.08

5Y Avg

46.08

SGMT

Sagimet Biosciences Inc.

vs BBOT

Market Cap

$285.42M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABEO

Abeona Therapeutics Inc.

vs BBOT

Market Cap

$285.55M

PE Ratio

N/A

TTM Avg

6.29

3Y Avg

6.29

5Y Avg

6.29

LRMR

Larimar Therapeutics, Inc.

vs BBOT

Market Cap

$288.79M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VNDA

Vanda Pharmaceuticals Inc.

vs BBOT

Market Cap

$271.81M

PE Ratio

N/A

TTM Avg

39.79

3Y Avg

40.81

5Y Avg

32.75

RCKT

Rocket Pharmaceuticals, Inc.

vs BBOT

Market Cap

$270.80M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MOBI

Mobia Medical, Inc. Common Stock

vs BBOT

Market Cap

$292.59M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
BridgeBio Oncology Therapeutics Inc. (BBOT)	$280.37M	N/A	N/A	N/A	N/A
Fulcrum Therapeutics, Inc. (FULC)vs ›	$281.54M	N/A	N/A	N/A	N/A
Standard BioTools Inc. (LAB)vs ›	$282.64M	N/A	N/A	N/A	N/A
Aurora Cannabis Inc. (ACB)vs ›	$284.31M	N/A	46.08	46.08	46.08
Sagimet Biosciences Inc. (SGMT)vs ›	$285.42M	N/A	N/A	N/A	N/A
Abeona Therapeutics Inc. (ABEO)vs ›	$285.55M	N/A	6.29	6.29	6.29
Larimar Therapeutics, Inc. (LRMR)vs ›	$288.79M	N/A	N/A	N/A	N/A
Vanda Pharmaceuticals Inc. (VNDA)vs ›	$271.81M	N/A	39.79	40.81	32.75
Rocket Pharmaceuticals, Inc. (RCKT)vs ›	$270.80M	N/A	N/A	N/A	N/A
Mobia Medical, Inc. Common Stock (MOBI)vs ›	$292.59M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$3.50

÷

Forward EPS (Est.)

$-2.59

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

BBOT PE Ratio Metrics

BBOT Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics